Intensity Therapeutics, Inc. (INTS) 10-Year Financial Performance & Capital Metrics

INTS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Show more

Revenue $0
EBITDA -$16M -99.1%
Net Income -$16M -54.4%
EPS (Diluted) -1.17 -34.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -202.34% -152.7%
ROIC -475.67%
Debt/Equity 0.05 +294.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM27.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.61%

ROCE

10Y Avg-141.21%

5Y Avg-158.5%

3Y Avg-201.89%

Latest-202.7%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	147K	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-147K	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	1%
Operating Expenses+	5.68M	6.22M	8.01M	7.55M	8.17M	16.59M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.24M	1.17M	2.14M	2.42M	3.39M	6.09M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	4.44M	5.05M	5.86M	5.13M	4.79M	10.5M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	17.22K	0	0	0
Operating Income+	-5.68M	-6.22M	-8.01M	-7.55M	-8.32M	-16.59M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.1%	-0.29%	0.06%	-0.1%	-0.99%
EBITDA+	-5.5M	-6.03M	-7.88M	-7.5M	-8.17M	-16.27M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-0.1%	-0.31%	0.05%	-0.09%	-0.99%
D&A (Non-Cash Add-back)	171.86K	0	0	0	147K	0
EBIT	-5.38M	-6.03M	-7.88M	-7.5M	-10.23M	-16.27M
Net Interest Income+	150.71K	74.01K	-14.16K	-79.3K	19K	314K
Interest Income	150.71K	74.01K	2.61K	2.48K	324K	314K
Interest Expense	0	0	16.77K	81.78K	305K	0
Other Income/Expense	295.7K	192.77K	118.58K	-32K	-2.22M	317K
Pretax Income+	-5.38M	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	0.97%	0.99%	1%	1%	1%	1%
Net Income+	-5.23M	-5.96M	-7.9M	-7.58M	-10.54M	-16.27M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.14%	-0.33%	0.04%	-0.39%	-0.54%
Net Income (Continuing)	-5.38M	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.40	-0.46	-0.60	-0.58	-0.87	-1.17
EPS Growth %	-	-0.15%	-0.3%	0.03%	-0.5%	-0.34%
EPS (Basic)	-0.40	-0.46	-0.60	-0.58	-0.87	-1.17
Diluted Shares Outstanding	13.1M	13.1M	13.1M	13.1M	13.71M	13.91M
Basic Shares Outstanding	13.1M	13.1M	13.1M	13.1M	13.71M	13.91M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.65M	9.48M	4.73M	1.45M	15.46M	3.36M
Cash & Short-Term Investments	8.39M	9.32M	4.54M	1.31M	14.78M	2.59M
Cash Only	3.83M	9.32M	4.54M	1.31M	8.56M	2.59M
Short-Term Investments	4.56M	0	0	0	6.22M	0
Accounts Receivable	33.63K	48.52K	51.26K	62.3K	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	166.47K	46.17K	69.28K	13.7K	6K	0
Total Non-Current Assets+	357.11K	671.94K	485.86K	306K	1.83M	1.42M
Property, Plant & Equipment	252.67K	490.24K	318.13K	139K	147K	122K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	75K	0	0	0	0	0
Other Non-Current Assets	29.44K	181.7K	167.74K	167K	1.68M	1.3M
Total Assets+	9.01M	10.15M	5.22M	1.76M	17.3M	4.78M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	0.13%	-0.49%	-0.66%	8.84%	-0.72%
Total Current Liabilities+	1.13M	1.35M	3.72M	6.82M	3.96M	1.75M
Accounts Payable	393.96K	222.71K	172.51K	603K	3.05M	1.22M
Days Payables Outstanding	-	-	-	-	7.57K	-
Short-Term Debt	117.19K	0	2.02M	4.35M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	6.52K	0	0	0	499K	56K
Current Ratio	7.67x	7.04x	1.27x	0.21x	3.91x	1.92x
Quick Ratio	7.67x	7.04x	1.27x	0.21x	3.91x	1.92x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	179.08K	10.36M	10.18M	10.04M	174K	110K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	143.08K	326.25K	143.57K	0	138K	110K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	36K	10.04M	10.04M	10.04M	36K	0
Total Liabilities	1.31M	11.71M	13.9M	16.86M	4.13M	1.86M
Total Debt+	260.27K	497.48K	2.34M	4.49M	158K	138K
Net Debt	-3.57M	-8.82M	-2.2M	3.18M	-8.4M	-2.45M
Debt / Equity	0.03x	-	-	-	0.01x	0.05x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-477.95x	-92.32x	-27.28x	-
Total Equity+	7.7M	-1.56M	-8.68M	-15.1M	13.16M	2.92M
Equity Growth %	-	-1.2%	-4.57%	-0.74%	1.87%	-0.78%
Book Value per Share	0.59	-0.12	-0.66	-1.15	0.96	0.21
Total Shareholders' Equity	7.7M	-1.56M	-8.68M	-15.1M	13.16M	2.92M
Common Stock	681	682	341	0	1K	2K
Retained Earnings	0	-23.18M	-31.07M	-38.65M	-50.52M	-66.78M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-17.15M	0	0	0	-17.3M	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.42M	-5.37M	-6.83M	-5.48M	-7.21M	-15.22M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.22%	-0.27%	0.2%	-0.32%	-1.11%
Net Income	-5.38M	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Depreciation & Amortization	0	0	0	179.04K	0	0
Stock-Based Compensation	561.38K	555.49K	0	1.17M	1.4M	3.07M
Deferred Taxes	0	0	0	-179.04K	0	0
Other Non-Cash Items	95.21K	116.83K	891.94K	178.86K	2.57M	76K
Working Capital Changes	306.91K	-12.03K	176.8K	756.69K	-633K	-2.1M
Change in Receivables	0	0	16.77K	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	202.55K	-171.26K	-50.2K	430.67K	1.63M	-2.27M
Cash from Investing+	1.7M	4.56M	0	0	-6.02M	6.35M
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	3.86M	6.29M	2.05M	2.25M	20.47M	2.9M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	25K	50K	0	-2.18M	-332K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-4.42M	-5.37M	-6.83M	-5.48M	-7.21M	-15.22M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.22%	-0.27%	0.2%	-0.32%	-1.11%
FCF per Share	-0.34	-0.41	-0.52	-0.42	-0.53	-1.09
FCF Conversion (FCF/Net Income)	0.84x	0.90x	0.86x	0.72x	0.68x	0.94x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-67.92%	-194%	-	-	-80.06%	-202.34%
Return on Invested Capital (ROIC)	-	-	-	-	-	-475.67%
Debt / Equity	0.03x	-	-	-	0.01x	0.05x
Interest Coverage	-	-	-477.95x	-92.32x	-27.28x	-
FCF Conversion	0.84x	0.90x	0.86x	0.72x	0.68x	0.94x

Frequently Asked Questions

Growth & Financials

Intensity Therapeutics, Inc. (INTS) grew revenue by 0.0% over the past year. Growth has been modest.

Intensity Therapeutics, Inc. (INTS) reported a net loss of $11.7M for fiscal year 2024.

Dividend & Returns

Intensity Therapeutics, Inc. (INTS) has a return on equity (ROE) of -202.3%. Negative ROE indicates the company is unprofitable.

Intensity Therapeutics, Inc. (INTS) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener